[1] [2] Testosterone, by contrast, is a well-established androgen hormone used therapeutically in the UK for conditions such as confirmed hypogonadism and, under specialist supervision, as part of gender-affirming hormone therapy (which is generally considered off-label use in the UK and requires specialist oversight)
GLP-1 receptor agonists as a pharmacological class are well-studied
[DOI] [PubMed] [Google Scholar] 208.Williams L.T., Barnes K., Ball L., Ross L.J., Sladdin I., Mitchell L.J
More realistic estimate: late 2027, with the drug available at pharmacies in early 2028
Headaches are a major contributor to reduced quality of life in IIH patients, and cognitive complaints have also been reported to improve when ICP is lowered